China has become the second largest and fastest emerging market for the bio-pharmaceuticals industry, making it essential for drug developers in the region to access complex information in their native language.1 Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today introduced a Simplified Chinese user interface for Cortellis to address this need. The Cortellis suite of life science intelligence solutions bring together data and insights on new product pipelines, deals, clinical trials and global regulatory requirements, plus predictive analytics on pipeline milestones and success rates – all now available using Simplified Chinese navigation and on-screen guidance.
The new Chinese interface serves an increasingly important market in the life sciences space. According to Cortellis, China is home to more than 1,300 biopharma companies (excluding generics companies), 218 biosimilar companies (more than any other country globally), and is considered a research hub for immuno-oncology with 153 companies using CAR-T cell therapy, second only to the U.S.
Available across the entire suite of Cortellis solutions, the interface makes research easier and more efficient. Users can easily access information in Simplified Chinese with one click, triggering automatic translation of all navigational and other interface elements.
“As the market in China continues to grow, the new Simplified Chinese user interface for Cortellis enables us to better support R&D efforts in the region, ultimately bringing life-saving drugs to market faster and more efficiently,” said Mukhtar Ahmed, President of Life Sciences at Clarivate Analytics. “This is the latest in a series of enhancements we’re introducing across the entire Cortellis portfolio, all of which are designed to enhance ease of use, provide greater value and ultimately accelerate innovation.”
Drawing on the industry’s broadest and deepest sources of competitive, regulatory and deals intelligence and analytics, Cortellis unlocks hidden insights in the data to help researchers assess the competitive landscape, understand global regulatory requirements, develop portfolio strategies, find the right partner and negotiate the best possible deal – faster and with greater accuracy compared to any other solution on the market. Currently, Cortellis curates 70,000+ pipeline products, 325,000+ clinical trials, 91,000+ deals, 165,000 company profiles, 200,000+ regulatory reference documents, and over 9 million patents worldwide.
References:
- China Pharmaceuticals 2018, Global Business Reports
